Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesotheliomia [corrected].
Sugarbaker
Paul H
PH
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D006979:Hyperthermia, Induced; D007274:Injections, Intraperitoneal / Q000379:methods; D008654:Mesothelioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D016019:Survival Analysis; D016896:Treatment Outcome